dihydroxyethyldithiocarbamate has been researched along with erythrosine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rieber, M; Rieber, MS; Viola-Rhenals, M | 1 |
1 other study(ies) available for dihydroxyethyldithiocarbamate and erythrosine
| Article | Year |
|---|---|
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chelating Agents; Copper; Ditiocarb; Fluoresceins; Humans; Hydroxyquinolines; Organometallic Compounds; Oxyquinoline; Zinc | 2006 |